Pasar al contenido principal

ESTUDIO DEL DEGRADOMA ASOCIADO AL MICROAMBIENTE TUMORAL DURANTE EL CANCER DE HIGADO CAUSADO POR OBESIDAD COMO NUEVA ESTRATEGIA TERAPEUTICA

PID2021-123652OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cathepsin D is essential for the degradomic shift of macrophages required to resolve liver fibrosis

  • Ruiz Blázquez, Paloma
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Moles, Anna
Background and objectives: Fibrosis contributes to 45% of deaths in industrialized nations and is characterized by an abnormal accumulation of extracellular matrix (ECM). There are no specific anti-fibrotic treatments for liver fibrosis, and previous unsuccessful attempts at drug development have focused on preventing ECM deposition. Because liver fibrosis is largely acknowledged to be reversible, regulating fibrosis resolution could offer novel therapeutical options. However, little is known about the mechanisms controlling ECM remodeling during resolution. Changes in proteolytic activity are essential for ECM homeostasis and macrophages are an important source of proteases. Herein, in this study we evaluate the role of macrophage-derived cathepsin D (CtsD) during liver fibrosis. Methods: CtsD expression and associated pathways were characterized in single-cell RNA sequencing and transcriptomic datasets in human cirrhosis. Liver fibrosis progression, reversion and functional characterization were assessed in novel myeloid-CtsD and hepatocyte-CtsD knock-out mice. Results: Analysis of single-cell RNA sequencing datasets demonstrated CtsD was expressed in macrophages and hepatocytes in human cirrhosis. Liver fibrosis progression, reversion and functional characterization were assessed in novel myeloid-CtsD (CtsDΔMyel) and hepatocyte-CtsD knock-out mice. CtsD deletion in macrophages, but not in hepatocytes, resulted in enhanced liver fibrosis. Both inflammatory and matrisome proteomic signatures were enriched in fibrotic CtsDΔMyel livers. Besides, CtsDΔMyel liver macrophages displayed functional, phenotypical and secretomic changes, which resulted in a degradomic phenotypical shift, responsible for the defective proteolytic processing of collagen I in vitro and impaired collagen remodeling during fibrosis resolution in vivo. Finally, CtsD-expressing mononuclear phagocytes of cirrhotic human livers were enriched in lysosomal and ECM degradative signaling pathways. Conclusions: Our work describes for the first-time CtsD-driven lysosomal activity as a central hub for restorative macrophage function during fibrosis resolution and opens new avenues to explore their degradome landscape to inform drug development., This work was mainly funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100 (AM); by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract RYC-2016-19731 (AM); by Pfizer grant #77131383 (AM); by Ministerio de Universidades fellowships FPU19/05357 (PRB) and FPU20/01367 (MFF); by MCIN/AEI/10.13039/501100011033/FEDER, UE contract PRE2022-101676 (JCP) and CSIC contract JAEINT_23_01245 (AdCC). Additional funding sources can be found in the financial support and sponsorship section of the manuscript.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

  • Martínez García de la Torre, Raquel A.
  • Ayuso García, Paula
  • Varela Rey, Marta María
  • Woodhoo, Ashwin
  • Sancho-Bru, Pau
Defining the trajectory of cells during differentiation and disease is key for uncovering the mechanisms driving cell fate and identity. However, trajectories of human cells remain largely unexplored due to the challenges of studying them with human samples. In this study, we investigate the proteome trajectory of iPSCs differentiation to hepatic stellate cells (diHSCs) and identify RORA as a key transcription factor governing the metabolic reprogramming of HSCs necessary for diHSCs’ commitment, identity, and activation. Using RORA deficient iPSCs and pharmacologic interventions, we show that RORA is required for early differentiation and prevents diHSCs activation by reducing the high energetic state of the cells. While RORA knockout mice have enhanced fibrosis, RORA agonists rescue multi-organ fibrosis in in vivo models. Notably, RORA expression correlates negatively with liver fibrosis and HSCs activation markers in patients with liver disease. This study reveals that RORA regulates cell metabolic plasticity, important for mesoderm differentiation, pericyte quiescence, and fibrosis, influencing cell commitment and disease.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lysosomal hydrolases, from waste-bags effectors to essential multipurpose enzymes in liver fibrosis

  • Fernández-Fernández, María
  • Ruiz-Blázquez, Paloma
  • Cacho-Pujol, Júlia
  • Moles, Anna
Lysosomal hydrolases were once considered effectors of the waste disposal system of the cell, the endo-lysosomal system. However, they are now recognized as highly selective enzymes, which can modulate the function of several substrates, contributing to essential homeostatic and pathological cellular processes. There are more than 50 different lysosomal hydrolases that display optimal activity in the pH present in the acidic cellular compartment but can also be found in other cellular locations. They can work alone or in cooperation with other proteases building signaling pathways or amplification cascades. In the context of liver fibrosis lysosomal hydrolases, especially cysteine cathepsins have been described to participate in several fundamental cellular events contributing to the development, progression, perpetuation, and resolution of liver fibrosis. This paper comprehensively reviews the current knowledge on the contribution of lysosomal hydrolases to liver fibrosis., AM’s research is supported by grants [RTI2018-097475-A-100] and [PID2021-123652OB-I00] funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”. Both MFF and PRB salaries were supported by FPU fellowships ([FPU20/01367] and [FPU19/05357], respectively) awarded by the Ministry of Universities, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

  • Martínez García de la Torre, Raquel A.
  • Vallverdú, Julia
  • Xu, Zhenqing
  • Ariño, Silvia
  • Ferrer-Lorente, Raquel
  • Zanatto, Laura
  • Mercado-Gómez, Maria
  • Aguilar-Bravo, Beatriz
  • Ruiz-Blázquez, Paloma
  • Fernandez-Fernandez, Maria
  • Navarro-Gascon, Artur
  • Blasco-Roset, Albert
  • Sànchez-Fernàndez-de-Landa, Paula
  • Pera, Joan
  • Romero-Moya, Damia
  • Ayuso Garcia, Paula
  • Martínez Sánchez, Celia
  • Sererols Viñas, Laura
  • Cantallops Vilà, Paula
  • Cárcamo Giráldez, Carmen I.
  • McQuillin, Andrew
  • Morgan, Marsha Y.
  • Moya-Rull, Daniel
  • Montserrat, Núria
  • Eberlé, Delphine
  • Staels, Bart
  • Antoine, Bénédicte
  • Azkargorta, Mikel
  • Lozano, Juan-José
  • Martínez-Chantar, Maria L.
  • Giorgetti, Alessandra
  • Elortza, Félix
  • Planavila, Anna
  • Varela-Rey, Marta
  • Woodhoo, Ashwin
  • Zorzano, Antonio
  • Graupera, Isabel
  • Moles, Anna
  • Coll, Mar
  • Affo, Silvia
  • Sancho-Bru, Pau
Defining the trajectory of cells during differentiation and disease is key for uncovering the mechanisms driving cell fate and identity. However, trajectories of human cells remain largely unexplored due to the challenges of studying them with human samples. In this study, we investigate the proteome trajectory of iPSCs differentiation to hepatic stellate cells (diHSCs) and identify RORA as a key transcription factor governing the metabolic reprogramming of HSCs necessary for diHSCs' commitment, identity, and activation. Using RORA deficient iPSCs and pharmacologic interventions, we show that RORA is required for early differentiation and prevents diHSCs activation by reducing the high energetic state of the cells. While RORA knockout mice have enhanced fibrosis, RORA agonists rescue multi-organ fibrosis in in vivo models. Notably, RORA expression correlates negatively with liver fibrosis and HSCs activation markers in patients with liver disease. This study reveals that RORA regulates cell metabolic plasticity, important for mesoderm differentiation, pericyte quiescence, and fibrosis, influencing cell commitment and disease., P.S-B. is supported by Instituto de Salud Carlos III (ISCIII) “PI20/00765”, PI23/00724, “FORT23/00002”, “DTS22/00032”, AGAUR, “2021 PROD 00035”, 23-0356; Dissecting the role of the 14q32 region in hepatoblastoma “Hblast14” Worldwide Cancer Research; PRYCO223102ARME; Scientific Foundation of the Spanish Association Against Cancer (AECC); Q6922, (B-ORG) Plan Complementario de Biotecnología aplicada a la Salud del Plan de Recuperación, Transformación y Resiliencia. Ministerio de Ciencia e Innovación and co-founded the European research and innovation program Horizon HORIZON-HLTH−2022-STAYHLTH-02 under agreement no. 101095679. R.A M-G is funded by Instituto de Salud Carlos III “FI18/00215”, S.A. received a grant from the Ministerio de Educación, Cultura y Deporte “FPU17/04992”, C.M is funded by Centro de Investigación en Red Enfermedades Hepáticas y Digestivas (CIBERehd). A.G. is supported by Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32) and CERCA Programme/ Generalitat de Catalunya for institutional support. J.P. is supported by La Marató de TV3 (202001-32). D.R-M. is supported by Deutsche José Carreras Leukämie-Stiftung (DJCLS 13 R/2022). A.M. was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100; by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract RYC 2016-19731; by Pfizer grant #77131383; P.R.B. was funded by Ministerio de Universidades fellowships FPU19/05357; M.F.F. was funded by FPU20/01367. M.V.-R. is supported by Proyecto PID2020-119486RB-100 (funded by MCIN/ AEI/10.13039/501100011033), Proyecto LABAECC2024 (funded by Asociación Española Contra el Cáncer, AECC), HORIZON-TMA-MSCA-Doctoral Networks 2021 (101073094), and Redes de Investigación 2022 (RED2022-134485-T). This study was funded by Instituto de Salud Carlos III through the Biobanks and Biomodels Platform and co‐funded by the European Union (PTC20/00013, PT20/00130, PT23/00009 and PTC23/00002 to N.M.) and by Instituto de Salud Carlos III and European Union—Next Generation EU, Plan de Recuperación Transformación y Resiliencia (TERAV/ISCIII RD21/0017/0018) to N.M; M.C. was funded by Ramon y Cajal programme from the Ministerio de Ciencia e Innovación RYC2019-026662-I. S.A. is funded by la Caixa Foundation “100010434” and the European Union’s Horizon 2020 under the Marie Skłodowska-Curie “847648”, PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312*. Ramon y Cajal program RYC2022-036321-I. (* Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them”)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Searching for novel cellular targets for MASLD and HCC within the humble lysosomal cathepsins

  • Castillo-Cruz, Alejandro del
  • Fernández-Fernández, María
  • Moles, Anna
Metabolic-associated steatotic liver disease (MASLD) and its pathological version, metabolic dysfunction-associated steatohepatitis (MASH), are becoming the main leading causes of chronic liver disease almost worldwide and are the fastest growing aetiology of hepatocellular carcinoma (HCC), especially in the Western countries. The combination of high incidence and morbidity with limited treatment options for both MASH and HCC highlights an urgent need for the discovery of novel therapeutic candidates to inform drug development. The importance of lysosomes and cathepsins, their most abundant hydrolases, has been overlooked for decades. They were considered organelles only involved in the recycling of macromolecules, with cathepsins simply being their effectors. Contrary to this traditional view, recent findings have shed new light on the lysosome and its enzymes as drivers of essential cellular processes, such as apoptosis and autophagy. Bringing lysosomal activity and the regulation of cathepsins into the spotlight of MASH and HCC research can open new avenues for the development of novel drugs based on targeting cathepsin-driven lysosomal activity and its associated pathological processes. This review comprehensively summarises the current knowledge on the role and contribution of lysosomal cathepsins to MASLD/MASH and HCC progression., This work was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants [PID2021-123652OB-I00] and [RTI2018-097475-A-100] (AM); by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract [RYC-2016-19731] (AM); by Pfizer grant [#77131383] (AM); by CSIC contract [JAEINT_23_01245] (AdCC); and by Ministerio de Universidades, Spain contract [FPU20/01367] (MFF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hepatic Stellate Cells Functional Heterogeneity in Liver Cancer

  • Sererols-Viñas, Laura
  • Garcia-Vicién, Gemma
  • Ruiz-Blázquez, Paloma
  • Lee, Ting-Fang
  • Lee, Youngmin A.
  • Gonzalez-Sanchez, Ester
  • Vaquero, Javier
  • Moles, Anna
  • Filliol, Aveline
  • Affò, Silvia
Hepatic stellate cells (HSCs) are the liver's pericytes, and play key roles in liver homeostasis, regeneration, fibrosis, and cancer. Upon injury, HSCs activate and are the main origin of myofibroblasts and cancer-associated fibroblasts (CAFs) in liver fibrosis and cancer. Primary liver cancer has a grim prognosis, ranking as the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) being the predominant type, followed by intrahepatic cholangiocarcinoma (iCCA). Moreover, the liver hosts 35% of all metastatic lesions. The distinct spatial distribution and functional roles of HSCs across these malignancies represent a significant challenge for universal therapeutic strategies, requiring a nuanced and tailored understanding of their contributions. This review examines the heterogeneous roles of HSCs in liver cancer, focusing on their spatial localization, dynamic interactions within the tumor microenvironment (TME), and emerging therapeutic opportunities, including strategies to modulate their activity, and harness their potential as targets for antifibrotic and antitumor interventions., S.A. is funded by the RYC2022-036321-I, MCIN/AEI/10.13039/501100011033/FEDER, Project PID2021-124694OA-I00, and The European Union grant agreement 101077312*. This work was also funded, in part, through the NIH/NCI Cancer Center Support Core Grant P30 CA008748 to A.A.F.; Y.A.L. is supported by 1R01DK133512 RSG-22-061-01-MM; A.M. is funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grant PID2021-123652OB-I00 and Pfizer grant #77131383; P.R.B. is funded by Ministerio de Universidades fellowships FPU19/05357. J.V. is funded by AEI, MICIN, through the project grant PID2022-141984OB-I00 and the “Ramon y Cajal” program RYC2021-034121-I.Figures Created in BioRender.*Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease

  • Ariño, Silvia
  • Ferrer-Lorente, Raquel
  • Serrano, Guillermo
  • Zanatto, Laura
  • Martínez-García de la Torre, Raquel A.
  • Gratacós-Ginès, Jordi
  • Rubio, Ana Belén
  • Pérez, Martina
  • Mateos-Sánchez, Carlos
  • Aguilar-Bravo, Beatriz
  • Atkinson, Stephen
  • Xu, Zhengqing
  • Cantallops-Vilà, Paula
  • Sererols-Viñas, Laura
  • Ruiz-Blázquez, Paloma
  • Rill, Aina
  • Fundora, Yiliam
  • Lozano, Juan José
  • Coll, Mar
  • Ochoa, Idoia
  • Affo, Silvia
  • Moles, Anna
  • Mereu, Elisabetta
  • Bataller, Ramón
  • Pose, Elisa
  • Sancho-Bru, Pau
Animal models poorly recapitulate advanced alcohol-associated liver disease (ALD), precluding the development of new treatments. Organoids have emerged as a powerful human-based preclinical tool; however, current patient-derived liver organoids fail to capture epithelial heterogeneity and require surgical resections, limiting their use in personalized disease modeling. Here, we describe the development of organoids from liver needle biopsies (b-Orgs) obtained from patients with ALD., This work has been supported by grants to P.S-B. Proyecto PI20/00765 and PI23/00724, funded by “Instituto de Salud Carlos III (ISCIII) co-financed by the European Union. By HORIZON-HLTH-2022- STAYHLTH-02, grant number 101095679, funded by the European Union. Project FORT23/00002, funded by Instituto de Salud Carlos III (ISCIII) "Programa FORTALECE del Ministerio de Ciencia, Innovación y Universidades". This work has also been co-financed for P.S-B by the Spanish Ministry of Science and Innovation with funds from the European Union NextGenerationEU, from the Recovery, Transformation and Resilience Plan (PRTR-C17.I1) and from the Autonomous Community of Catalonia within the framework of the Biotechnology Plan Applied to Health (Q6922). S.A. received a fellowship from the Ministerio de Educación, Cultura y Deporte (FPU17/04992). R.A. M-G. was funded by the Instituto de Salud Carlos III, PFIS (FI18/00215). B.A-B. was funded by Instituto de Salud Carlos III, PFIS (FI16/00203). M.C. is funded by the Ramon y Cajal program from the Ministerio de Ciencia e Innovación RYC2019-026662-I and by the State Plan of Scientific and Technical Research and Innovation PID2021-125195OB-I00. S.A. is funded by the MCIN/AEI/10.13039/501100011033 by “ERDF A way of making Europe” (PID2021-124694OA-I00) and the European Union grant agreement 101077312. A.M. was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100; by MCIN/AEI/10.13039/501100011033; by Pfizer grant #77131383; and the contract RYC-2016-19731. P.R-B received a fellowship from the Spanish Ministry of Education, Culture and Sports, FPU program (FPU19/05357)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cathepsin D is essential for the degradomic shift of macrophages required to resolve liver fibrosis

  • Ruiz Blázquez, Paloma
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Moles, Anna
Background and objectives: Fibrosis contributes to 45% of deaths in industrialized nations and is characterized by an abnormal accumulation of extracellular matrix (ECM). There are no specific anti-fibrotic treatments for liver fibrosis, and previous unsuccessful attempts at drug development have focused on preventing ECM deposition. Because liver fibrosis is largely acknowledged to be reversible, regulating fibrosis resolution could offer novel therapeutical options. However, little is known about the mechanisms controlling ECM remodeling during resolution. Changes in proteolytic activity are essential for ECM homeostasis and macrophages are an important source of proteases. Herein, in this study we evaluate the role of macrophage-derived cathepsin D (CtsD) during liver fibrosis. Methods: CtsD expression and associated pathways were characterized in single-cell RNA sequencing and transcriptomic datasets in human cirrhosis. Liver fibrosis progression, reversion and functional characterization were assessed in novel myeloid-CtsD and hepatocyte-CtsD knock-out mice. Results: Analysis of single-cell RNA sequencing datasets demonstrated CtsD was expressed in macrophages and hepatocytes in human cirrhosis. Liver fibrosis progression, reversion and functional characterization were assessed in novel myeloid-CtsD (CtsDΔMyel) and hepatocyte-CtsD knock-out mice. CtsD deletion in macrophages, but not in hepatocytes, resulted in enhanced liver fibrosis. Both inflammatory and matrisome proteomic signatures were enriched in fibrotic CtsDΔMyel livers. Besides, CtsDΔMyel liver macrophages displayed functional, phenotypical and secretomic changes, which resulted in a degradomic phenotypical shift, responsible for the defective proteolytic processing of collagen I in vitro and impaired collagen remodeling during fibrosis resolution in vivo. Finally, CtsD-expressing mononuclear phagocytes of cirrhotic human livers were enriched in lysosomal and ECM degradative signaling pathways. Conclusions: Our work describes for the first-time CtsD-driven lysosomal activity as a central hub for restorative macrophage function during fibrosis resolution and opens new avenues to explore their degradome landscape to inform drug development., This work was mainly funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100 (AM); by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract RYC-2016-19731 (AM); by Pfizer grant #77131383 (AM); by Ministerio de Universidades fellowships FPU19/05357 (PRB) and FPU20/01367 (MFF); by MCIN/AEI/10.13039/501100011033/FEDER, UE contract PRE2022-101676 (JCP) and CSIC contract JAEINT_23_01245 (AdCC). Additional funding sources can be found in the financial support and sponsorship section of the manuscript.